Cyclosporine C2 monitoring is superior to C0 in predicting acute cellular rejection in heart transplant recipients in Taiwan
- PMID: 15561260
- DOI: 10.1016/j.transproceed.2004.08.115
Cyclosporine C2 monitoring is superior to C0 in predicting acute cellular rejection in heart transplant recipients in Taiwan
Abstract
The cyclosporine (CsA) blood concentration at 2 hours postdose (C2) has been shown to be better than trough level (C0) to predict acute cellular rejection (ACR) in solid organ transplantations. We tried to assess the superiority of C2 monitoring to C0 in heart transplantation (HTx). Prospective data were collected from the HTx recipients from November 1991 to April 2003. The 100 patients surviving longer than 3 months after HTx, provided 237 sample sets, with ACR graded by endomyocardial biopsy (EMB) and concurrent C0 and C2 levels. ACR was defined as International Society of Heart and Lung Transplantation (ISHLT) grade lb or higher. Nonparametric methods, logistic regression model, and receiver operating characteristic (ROC) analysis were used. There was no significant demographic heterogeneity between ACR and non-ACR groups. C2 was significantly lower in ACR than non-ACR groups (P = .0192) whereas C0 showed no significant difference. In the logistic regression model, C2 was a significant predictor against ACR (P = .026, odds ratio = 0.76 per 100 ng/mL), but C0 was not. ROC analysis showed that C2 of 600 ng/mL might provide the optimal cut-off point, with a sensitivity of 51.23% and a specificity of 71.43%, but C0 did not show this association. In conclusion, C2 monitoring is superior to C0 for predicting ACR in HTx. ACR should be suspected when the C2 value is below 600 ng/mL.
Similar articles
-
Advantages of C2 monitoring to avoid acute rejection in pediatric heart transplant recipients.J Heart Lung Transplant. 2006 Jun;25(6):619-25. doi: 10.1016/j.healun.2006.02.002. J Heart Lung Transplant. 2006. PMID: 16730566
-
Cyclosporine C2 levels have impact on incidence of rejection in de novo lung but not heart transplant recipients: the NOCTURNE study.J Heart Lung Transplant. 2009 Sep;28(9):919-26. doi: 10.1016/j.healun.2009.05.022. J Heart Lung Transplant. 2009. PMID: 19716045
-
C2 is superior to C0 as predictor of renal toxicity and rejection risk profile in stable heart transplant recipients.Transpl Int. 2005 Jan;18(1):116-24. doi: 10.1111/j.1432-2277.2004.00001.x. Transpl Int. 2005. PMID: 15612993
-
History of C2 monitoring in heart and liver transplant patients treated with cyclosporine microemulsion.Transplant Proc. 2004 Mar;36(2 Suppl):442S-447S. doi: 10.1016/j.transproceed.2004.01.004. Transplant Proc. 2004. PMID: 15041383 Review.
-
Is C2 monitoring or another limited sampling strategy superior to C0 monitoring in improving clinical outcomes in adult liver transplant recipients?Ther Drug Monit. 2006 Oct;28(5):637-42. doi: 10.1097/01.ftd.0000243965.97964.ca. Ther Drug Monit. 2006. PMID: 17038878 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous